Oxurion

Oxurion

Belgium - Leuven
Biotechnology

Focus: Ophthalmic Medicines

Oxurion is a life sciences company focused on Ophthalmic Medicines.

Ophthalmology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

Retinal and Cognitive Dysfunction in Type 2 Diabetes
Retinal Function
N/A
THR-687 dose level 1
Diabetes Mellitus
Phase 1
Clinical Trials (1)
NCT03666923A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
Phase 1
Phase 1
THR-149 dose level 1
Diabetes Mellitus
Phase 1
Clinical Trials (1)
NCT03511898A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)
Phase 1
ocriplasmin 0.0625mg
Diabetic Retinopathy
Phase 2
Clinical Trials (1)
NCT02681809A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
Phase 2
Ranibizumab 0.5mg
Diabetes Mellitus
Phase 2
Clinical Trials (1)
NCT03499223A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)
Phase 2
THR-149 dose level 1
Diabetes Mellitus
Phase 2
Clinical Trials (1)
NCT04527107A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema
Phase 2
Phase 2
Clinical Trials (1)
NCT03669393A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)
Phase 2
THR-687 dose level 1
Diabetes Mellitus
Phase 2
Clinical Trials (1)
NCT05063734A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.
Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2024
Portfolio: 7 clinical trials